S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
UPB · Upstream Bio, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$2.79
-0.01
(-0.36%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$2.79
$2.77
$2.95
52-WEEK RANGE
$2.79
$2.74
$33.68
What's happening
- UPB is down 0.36% today, trading at $2.79. — Live quote
- It's trading within 3% of its 52-week low ($2.74). (Finnhub fundamentals)
- Volume today (110,601) is well below its 3-month average of 723,500. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.73 actual vs. $-0.77 estimated (+5.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 7
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (12 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
UPB
-89.61%
vs S&P 500
-102.39%
1-YEAR RETURN
UPB
-87.77%
vs S&P 500
-102.33%
6-MONTH RETURN
UPB
-72.08%
3-MONTH RETURN
UPB
-59.60%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.73
Est. $-0.77
BEAT +5.0%
2026-04-26 (Q1 2026)
$-0.75
Est. $-0.78
BEAT +4.0%
2026-01-26 (Q4 2025)
$-0.79
Est. $-0.71
MISS -11.2%
2025-10-26 (Q3 2025)
$-0.63
Est. $-0.79
BEAT +20.2%
Valuation Measures & Ratios
Enterprise Value4$75.1M
Forward P/E5—
PEG Ratio6-0.02
Price / Sales (TTM1)48.91
Price / Book71.39
EV4 / Revenue23.77
EV4 / EBITDA—
Profit Margin-4955.67%
Operating Margin-5382.65%
Return on Equity (ROE8)-48.40%
Return on Assets (ROA9)-46.57%
Avg Volume (3M)723,500
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $376.1M | $485.5M | $1.01B | $593.5M | $327.8M |
| P/E | -2.44 | -3.43 | -8.61 | -6.06 | -4.76 |
| Price/Sales | 109.74 | 150.77 | 360.77 | 226.55 | 141.10 |
| Price/Book | 1.39 | 1.60 | 2.66 | 1.45 | 0.74 |
| EV/Revenue | 86.57 | 120.73 | 334.93 | 209.20 | 110.40 |
| EV/EBITDA | -1.77 | -2.47 | -7.04 | — | — |
| ROE | -56.84% | -46.57% | -30.90% | -23.95% | -15.45% |
| ROA | -54.77% | -44.51% | -29.90% | -23.28% | -15.09% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short4,514,865
Change from Prior Settlement+0.54%
% of Float—
Days to Cover (Short Ratio)7.68
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-09-17; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -17.5% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -4955.7%. Finnhub fundamentals ↗
- Trailing 52-week price return is -87.8%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on UPB
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $773.0K | $1.0M | $683.0K | $937.0K | $566.0K | $607.0K | $510.0K | $640.0K |
| Operating income | -$42.4M | -$43.6M | -$37.8M | -$44.3M | -$32.0M | -$18.9M | -$17.5M | -$15.0M |
| Net income | -$39.7M | -$40.6M | -$33.7M | -$40.0M | -$27.3M | -$16.0M | -$14.7M | -$10.9M |
| EPS (diluted) | $-0.73 | $-0.75 | $-0.63 | $-0.74 | $-0.51 | $-6.96 | $-6.50 | $-4.68 |
| EPS (basic) | $-0.73 | $-0.75 | $-0.63 | $-0.74 | $-0.51 | $-6.96 | $-6.50 | $-4.68 |
| Operating margin | -$5.5K | -$4.2K | -$5.5K | -$4.7K | -$5.7K | -$3.1K | -$3.4K | -$2.3K |
| Net margin | -$5.1K | -$3.9K | -$4.9K | -$4.3K | -$4.8K | -$2.6K | -$2.9K | -$1.7K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $281.2M | $318.1M | $353.8M | $391.2M | $420.5M | $456.2M | $481.7M | $232.7M |
| Total liabilities | $10.2M | $14.1M | $14.0M | $12.6M | $11.8M | $10.6M | $11.9M | $12.1M |
| Stockholders' equity | $271.0M | $304.0M | $339.8M | $378.6M | $408.7M | $445.6M | $469.9M | -$160.3M |
| Total current assets | $279.6M | $316.3M | $351.8M | $389.0M | $418.3M | $453.8M | $479.2M | $227.3M |
| Total current liabilities | $10.0M | $13.7M | $13.5M | $11.9M | $10.9M | $9.6M | $10.7M | $10.9M |
| Cash & equivalents | $79.4M | $96.7M | $101.6M | $72.2M | $45.5M | $71.3M | $325.9M | $32.9M |
| Marketable securities (current) | $181.9M | $197.9M | $239.9M | $300.3M | $348.1M | $360.1M | $144.6M | $187.7M |
| Accounts receivable | $772.0K | $1.0M | $668.0K | $683.0K | $937.0K | $566.0K | $613.0K | $607.0K |
| Other current assets | $1.2M | — | $727.0K | — | — | — | — | — |
| Property, plant & equipment | $460.0K | $510.0K | $559.0K | $616.0K | $544.0K | $539.0K | $582.0K | $578.0K |
| Goodwill | — | — | — | — | — | — | $0 | — |
| Accounts payable | $2.3M | $1.7M | $2.7M | $4.0M | $2.6M | $4.7M | $4.0M | $4.9M |
| Other current liabilities | — | — | — | $55.0K | — | — | — | $118.0K |
| Common stock & paid-in capital | $54.0K | $54.0K | $54.0K | $56.0K | $54.0K | $53.0K | $53.0K | $3.0K |
| Retained earnings | -$414.5M | -$374.8M | -$334.2M | -$291.8M | -$258.0M | -$218.1M | -$190.8M | -$169.5M |
| Accumulated other comprehensive income (loss) | -$123.0K | $100.0K | $530.0K | $493.0K | $258.0K | $368.0K | -$25.0K | $351.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$35.6M | -$47.9M | -$30.6M | -$22.2M | -$39.2M | -$41.2M | -$19.6M | -$14.0M |
| Investing cash flow | $15.8M | $42.4M | $58.9M | $48.2M | $12.8M | -$213.4M | $41.9M | $1.4M |
| Financing cash flow | $2.5M | $598.0K | $1.1M | $760.0K | $612.0K | -$34.0K | $270.6M | -$1.6M |
| Free cash flow | -$35.6M | — | -$30.7M | -$22.3M | -$39.3M | — | -$19.8M | -$14.3M |
| Capital expenditures | $0 | — | $54.0K | $64.0K | $47.0K | — | $185.0K | $326.0K |
| Depreciation & amortization | $50.0K | $49.0K | $57.0K | $46.0K | $42.0K | $43.0K | $49.0K | $14.0K |
| Share-based compensation | $4.4M | $4.6M | $2.5M | $2.6M | $2.6M | $2.6M | $2.1M | $1.9M |
| Change in accounts payable | $604.0K | -$1.0M | -$1.2M | $1.4M | -$2.2M | $711.0K | -$871.0K | -$174.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $2.9M | $2.4M | $2.4M |
| Operating income | -$160.4M | -$77.8M | -$40.1M |
| Net income | -$143.4M | -$62.8M | -$20.5M |
| EPS (diluted) | $-2.66 | $-5.58 | $-12.95 |
| EPS (basic) | $-2.66 | $-5.58 | $-12.95 |
| Operating margin | -$5.6K | -$3.3K | -$1.7K |
| Net margin | -$5.0K | -$2.7K | -$863 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Total assets | $353.8M | $481.7M | $117.2M | — |
| Total liabilities | $14.0M | $11.9M | $9.4M | — |
| Stockholders' equity | $339.8M | $469.9M | -$123.1M | -$106.2M |
| Total current assets | $351.8M | $479.2M | $117.0M | — |
| Total current liabilities | $13.5M | $10.7M | $6.5M | — |
| Cash & equivalents | $101.6M | $325.9M | $25.8M | — |
| Marketable securities (current) | $239.9M | $144.6M | $84.0M | — |
| Accounts receivable | $668.0K | $613.0K | $98.0K | — |
| Property, plant & equipment | $559.0K | $582.0K | $159.0K | — |
| Goodwill | — | $0 | — | — |
| Accounts payable | $2.7M | $4.0M | $2.0M | — |
| Common stock & paid-in capital | $54.0K | $53.0K | $3.0K | — |
| Retained earnings | -$334.2M | -$190.8M | -$128.0M | — |
| Accumulated other comprehensive income (loss) | $530.0K | -$25.0K | $21.0K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Operating cash flow | -$133.3M | -$59.2M | -$37.9M |
| Investing cash flow | -$93.5M | -$59.5M | -$82.8M |
| Financing cash flow | $2.4M | $418.9M | $129.6M |
| Free cash flow | -$133.4M | -$59.7M | -$38.1M |
| Capital expenditures | $165.0K | $511.0K | $144.0K |
| Depreciation & amortization | $188.0K | $89.0K | $60.0K |
| Share-based compensation | $10.3M | $6.0M | $3.3M |
| Change in accounts payable | -$1.3M | $2.0M | $1.3M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding UPB as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Insider activity is not available for this symbol right now.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 02:56 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-17 | 4 | 2026-09-16 | View on SEC.gov → |
| 2026-09-17 | 4 | 2026-09-16 | View on SEC.gov → |
| 2026-09-17 | 4 | 2026-09-16 | View on SEC.gov → |
| 2026-09-17 | 4 | 2026-09-16 | View on SEC.gov → |
| 2026-09-17 | 4 | 2026-09-16 | View on SEC.gov → |
| 2026-09-01 | 8-K | 2026-09-01 | View on SEC.gov → |
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
Recent news
Headlines about UPB (Upstream Bio, Inc.). Links open the publisher — we don’t host full articles.
-
Upstream Bio (UPB) Falls 18.10% to $2.76 as Shares Test Key Support - Wave Truncation
https://www.dars.gov.et/ · 2026-10-18 -
Which of Upstream Bio (NASDAQ:UPB), Biofrontera (NASDAQ:BFRI), Aldeyra Therapeutics (NASDAQ:ALDX), KALA BIO (NASDAQ:KALA) or Inovio Pharmaceuticals (NASDAQ:INO) Is the Best Biotech or Pharma Gainer in Pre-Market?
kalkine.ca · 2026-10-16 -
Upstream Bio (UPB) Slides 2.63% to $3.33 as Shares Drift Toward Lower Support - PCR Spike
https://www.siam.in/ · 2026-10-15 -
Here's Why We're Watching Upstream Bio's (NASDAQ:UPB) Cash Burn Situation
Moomoo · 2026-10-15 -
Upstream Bio stock jumps 8% on Phase 2 severe asthma data
Seeking Alpha · 2026-09-08 -
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
Yahoo Finance · 2026-09-08 -
Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027
Yahoo Finance · 2026-09-01 -
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Yahoo Finance · 2026-08-11
No headlines in this category right now — try “All”.